DMG-ACT — Building a Discovery Engine Around the Trial

DMG-ACT (Diffuse Midline Glioma – Adaptive Combinatorial Therapy) is a global, multidisciplinary initiative transforming how children with DIPG and DMG are treated. Built on the belief that no single therapy will defeat these heterogeneous and aggressive tumors, DMG-ACT brings together world-leading clinicians, scientists, and institutions to rapidly identify, test, and advance the most promising treatment combinations for children battling these cancers.

In 2022, DMG-ACT expanded beyond clinical enrollment to become a global discovery platform. Researchers conducted large-scale preclinical drug screens, evaluating more than 100 compounds to identify promising candidates for combination therapy. At the same time, DMG-ACT established specialized scientific cores—including liquid biopsy, metabolomics, bioinformatics, and in vivo modeling—to accelerate translational insight.

This year also marked a surge in peer-reviewed publications directly enabled by DMG-ACT infrastructure, advancing understanding of imipridones, tumor metabolism, treatment response, and resistance mechanisms in DMG. ChadTough’s investment supported the integration of laboratory science with clinical trial execution, ensuring that discoveries in the lab could rapidly inform patient-facing trial arms.